HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence : study protocol for a phase III, multicenter randomized trial with two parallel groups of patients

This item is licensed under: Creative Commons Attribution 4.0 International

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1186/s13063-019-3904-4


Title: Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence : study protocol for a phase III, multicenter randomized trial with two parallel groups of patients
Authors: Yamamoto, Haruko Browse this author
Hamasaki, Toshimitsu Browse this author →KAKEN DB
Onda, Kaori Browse this author
Nojiri, Takashi Browse this author
Aragaki, Masato Browse this author
Horie, Nao Browse this author
Sato, Norihiro Browse this author
Hida, Yasuhiro Browse this author →KAKEN DB
Keywords: Beta-blocker
Cancer recurrence
Clinical trial
Lung cancer
Landiolol
Issue Date: 11-Dec-2019
Publisher: BioMed Central
Journal Title: Trials
Volume: 20
Issue: 1
Start Page: 715
Publisher DOI: 10.1186/s13063-019-3904-4
Abstract: Background: Recurrence of cancer after curative surgery is a major problem after most cancer treatments. Increased sympathetic activity during the perioperative period could promote cancer cell invasion to blood vessels and angiogenesis, resulting in cancer metastasis. Recent studies showed that use of beta blockers can be associated with the prolonged survival of patients with cancer. The objective of this study is to evaluate the preventive effects of landiolol hydrochloride, which is an ultra-short-acting beta-1-selective blocker that has been developed in Japan, on reducing recurrence of cancer after curative surgery for patients with lung cancer. Methods: The present study is a phase III, multicenter, randomized trial with two parallel groups of patients with lung cancer, comparing surgery alone and surgery with landiolol administration for three days during the perioperative period. A total of 400 patients will be enrolled from 12 Japanese institutions. The primary endpoint is two-year relapse-free survival and overall survival after curative surgery for lung cancer. The secondary endpoints are additional treatment after recurrence of cancer, safety events, and the incidence of postoperative complications. Discussion: The principal question addressed in this trial is whether landiolol can reduce recurrence of cancer after curative surgery for lung cancer.
Rights: https://creativecommons.org/licenses/by/4.0/
Type: article
URI: http://hdl.handle.net/2115/76731
Appears in Collections:国際連携研究教育局 : GI-CoRE (Global Institution for Collaborative Research and Education : GI-CoRE) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University